Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours.

Lepage, C; Dahan, L; Bouarioua, N; Toumpanakis, C; Legoux, J; Le Malicot, K; Guimbaud, R; Smith, D; Tougeron, D; Lievre, A; Cadiot, G; Di Fiore, F; Bouhier-Leporrier, K; Hentic, O; Faroux, R; Pavel, M; Borbath, I; Valle, Juan W; Rinke, A; Scoazec, J; Ducreux, M; Walter, T

Affiliation

Department of Digestive Oncology, Burgundy Franche-Conte University, University hospital Dijon, Dijon, France

Issue Date

2017-03-11

Metadata

Show full item record

Abstract

Patients with metastatic or locally advanced, non-resectable, grade 1 or 2 well-differentiated duodeno-pancreatic (WDDP) NETs are treated following European guidelines. Patients (Pts) with aggressive disease, i.e. progressive and/or symptomatic metastases and/or with significant hepatic invasion (>30-50%), and/or bone metastases, anti-tumour therapy should receive systemic combination of chemotherapy once disease control is obtained.

Citation

Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours. 2017, 49(5):568-571 Dig Liver Dis

Journal

Digestive and Liver Disease

URI

http://hdl.handle.net/10541/620324

DOI

10.1016/j.dld.2017.02.004

PubMed ID

28292641

Type

Article

Language

ISSN

1878-3562

Collections

All Christie Publications